Context Therapeutics Inc.
CNTXNasdaq
$0.60
↓ -2.4%Jul 17 close · end-of-day
Price
1Y↓ -27.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$57.1M
Enterprise Value
$2.6M
P/E
—
P/S
—
P/B
1.1
EV/EBITDA
—
PEG
—
FCF Yield
-57.5%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$40.2M
Free Cash Flow (TTM)
-$32.8M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-77.1%
ROIC
—
Debt / Equity
—
Net Cash
$54.5M
Return 1Y
-34.2%
Company profile
Context Therapeutics Inc. develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of progesterone receptor. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody.
- CEO
- Martin A. Lehr
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 7
- Headquarters
- Pennsylvania
- Website
- contexttherapeutics.com
Earnings
CNTX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.09↑ +80.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$2.6M | -$10.5M | -$15.4M | -$25.1M | -$29.9M | -$39.7M |
| Net income | $6.6M | -$10.5M | -$14.8M | -$24.0M | -$26.7M | -$36.1M |
| Diluted EPS | -$3.96 | -$3.69 | -$0.93 | -$1.50 | -$0.46 | -$0.38 |
| Operating cash flow | -$1.0M | -$8.8M | -$13.5M | -$21.0M | -$14.6M | -$26.4M |
| Free cash flow | — | -$8.8M | -$13.6M | -$21.0M | -$14.6M | -$26.4M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.1M | -$18.7M | -$4.3M | -$5.5M | -$9.8M | -$10.6M | -$13.8M | -$9.3M |
| Net income | -$2.3M | -$17.5M | -$3.3M | -$4.6M | -$8.8M | -$9.7M | -$13.0M | -$8.7M |
| Diluted EPS | -$0.04 | -$0.22 | $0.03 | -$0.05 | -$0.09 | -$0.10 | -$0.14 | -$0.09 |
| Operating cash flow | -$3.4M | -$1.9M | -$4.9M | -$5.0M | -$5.8M | -$6.6M | -$8.9M | -$11.4M |
| Free cash flow | -$3.4M | -$1.9M | -$4.9M | -$5.1M | -$5.8M | -$6.6M | -$8.9M | -$11.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 10, 2026
Jul 6, 2026
Jun 15, 2026
- 34d agoCNTX Hits Worst Day In History After Ovarian Cancer Trial Data — But Analysts See Buying Opportunity In Dipstocktwits.com
- 35d agoSmall Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Studyfinance.yahoo.com
- 35d agoContext Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.